Rational design of a triple-type human papillomavirus vaccine by compromising viral-type specificity

通过妥协病毒类型特异性合理设计三型人乳头瘤病毒疫苗

阅读:9
作者:Zhihai Li, Shuo Song, Maozhou He, Daning Wang, Jingjie Shi, Xinlin Liu, Yunbing Li, Xin Chi, Shuangping Wei, Yurou Yang, Zhiping Wang, Jinjin Li, Huilian Qian, Hai Yu, Qingbing Zheng, Xiaodong Yan, Qinjian Zhao, Jun Zhang, Ying Gu, Shaowei Li, Ningshao Xia

Abstract

Sequence variability in surface-antigenic sites of pathogenic proteins is an important obstacle in vaccine development. Over 200 distinct genomic sequences have been identified for human papillomavirus (HPV), of which more than 18 are associated with cervical cancer. Here, based on the high structural similarity of L1 surface loops within a group of phylogenetically close HPV types, we design a triple-type chimera of HPV33/58/52 using loop swapping. The chimeric VLPs elicit neutralization titers comparable with a mix of the three wild-type VLPs both in mice and non-human primates. This engineered region of the chimeric protein recapitulates the conformational contours of the antigenic surfaces of the parental-type proteins, offering a basis for this high immunity. Our stratagem is equally successful in developing other triplet-type chimeras (HPV16/35/31, HPV56/66/53, HPV39/68/70, HPV18/45/59), paving the way for the development of an improved HPV prophylactic vaccine against all carcinogenic HPV strains. This technique may also be extrapolated to other microbes.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。